• Strategy
  • Payers
  • AI
  • Cybersecurity
  • Device Development
  • Studies/Published Research
  • Ethics
  • Regulatory
  • Digital Biomarkers
  • Data Science
  • Companion Diagnostics
  • Clinical Care
  • Digital Therapeutics
  • Academic Research
  • Virtual Reality
  • RWE
  • Digital Endpoints
  • Medical Devices (Class II and Class III)
  • Commercialization
  • Clinical Trials
  • Drug-Device Combinations
  • SaMD
  • Remote Patient Monitoring
  • Patient Engagement
  • Profiles/Q&A

Green Inhaler Producer Receives Grant From UK Government

News
Article

Kindeva Drug Delivery will use the money to support its green inhaler production.

The UK government’s Life Sciences Innovation Manufacturing Fund provided a grant to Kindeva Drug Delivery, opening up an investment of over $41 million. The investment will go towards Kindeva’s inhaler manufacturing and sustainability.

In a press release, Kindeva global chief commercial officer David Stevens said, “This joint investment of public and private funds creates myriad new opportunities for Kindeva colleagues within the U.K., as significant technical and regulatory expertise is required in the development and manufacturing of complex inhalation products. This investment provides Kindeva with a springboard to expand our capabilities and capacity, while simultaneously partnering with leading pharmaceutical companies around the world to bring the next generation of green inhalers to market — with a common goal of safeguarding access to necessary therapies for patients and reducing our impact on the planet.”

Kindeva produces green pressurized metered-dose inhalers. The money will be used to support a new manufacturing facility in Loughborough, improvements to the company’s site at Clitheroe, and other opportunities to promote green transitions.

© 2024 MJH Life Sciences

All rights reserved.